ClinicalTrials.gg
CompletedNCT02003144Updated Aug 23, 2022Results posted

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

A Phase 3 interventional study of eculizumab in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 69 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-23.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
119
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Neuromyelitis Optica by AstraZeneca — 3 open to participants now, 5 under way, 3 of them phase 3. Neuromyelitis Optica · AstraZeneca.

Started
2015
with 1 other
Phase 3
5 of 11
1 open now
Registered
2nd of 11
by date

Among the 11 studies in Neuromyelitis Optica by AstraZeneca, this one is one of 2 that started in 2015, is one of 5 in phase 3, and was the 2nd registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

3 of the 11 studies in Neuromyelitis Optica by AstraZeneca are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Neuromyelitis Optica by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.

Read the detailed description

This study is an open label extension study to confirm the long term safety and efficacy of eculizumab in subjects with relapsing NMO who have completed the initial double-blind, randomized, placebo-controlled trial ECU-NMO-301.

03

Conditions studied

  • Neuromyelitis Optica
  • Neuromyelitis Optica Spectrum Disorder

Keywords

  • Long-term safety study
  • Extension trial
  • Eculizumab
  • Neuromyelitis Optica Spectrum Disorder
  • Devic's disease
  • Transverse Myelitis
  • Optic Neuritis
  • Relapse
  • NMO-IgG
  • CNS Autoimmune Disorders
  • Demyelinating Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Patient completed the ECU-NMO-301 trial
  2. Patient has given written

Key Exclusion Criteria:

  1. Patients who have withdrawn from the ECU-NMO-301 trial as a result of an AE related to trial drug
  2. Female patients who are pregnant, breastfeeding, or intend to conceive during the course of the trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Eculizumab

    Eculizumab intravenous infusion every two weeks.

    Biological: eculizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events

    An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent adverse events (TEAEs) were defined as an AE with onset on or after the first study drug dose in Study ECU-NMO-302. A serious adverse event (SAE) was defined as an untoward medical occurrence that at any dose either results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline up to end of study (up to 6.5 years)

  2. Number of Participants With At Least 1 Post Baseline Columbia-Suicide Severity Rating Scale (C-SSRS) Assessment (Suicide-Related Thoughts or Behaviours) Abnormality

    The C-SSRS is a validated questionnaire to capture occurrence, severity, and frequency of suicide-related thoughts and behaviours, and has a binary response (yes/no). Suicidal Ideation: a "yes" answer to any one of 5 suicidal ideation questions: Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Planned) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; and Active Suicidal Ideation with Specific Plan and Intent. Suicidal Behaviour: a "yes" answer to any of 5 suicidal behaviour questions: Preparatory Acts or Behaviour, Aborted Attempt, Interrupted Attempt, Actual Attempt (non-fatal), and Completed Suicide. Suicidal Ideation or Behaviour: a "yes" answer to the following question: Self-injurious behaviour without suicidal intent.

    Time frame: Baseline up to end of study (up to 6.5 years)

  3. Number of Participants With An On-trial Relapse as Determined by The Treating Physician

    An On-trial Relapse was defined as a new onset of neurologic symptoms or worsening of existing neurologic symptoms with an objective change (clinical sign) on neurologic examination that persisted for more than 24 hours as confirmed by the treating physician.

    Time frame: Baseline up to end of study (up to 6.5 years)

  4. On-Trial Annualized Relapse Rate (ARR) as Determined by The Treating Physician

    The On-trial ARR was computed as the total number of relapses divided by the total number of participant years in the study period.

    Time frame: Baseline up to end of study (up to 6.5 years)

Secondary outcomes

  1. Change From Baseline in Expanded Disability Status Scale (EDSS) Score

    Disease-related disability was measured by the EDSS. The EDSS quantifies disability in 8 Functional Systems (FS) and allows neurologists to assign a Functional System Score (FSS) in each of these. The Functional Systems are pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral, and other. The EDSS is an ordinal clinical rating scale that ranges from 0 (normal neurologic examination) to 10 (death) in half-point increments. A decrease in score indicates improvement. Baseline was defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.

    Time frame: Baseline, Weeks 52, 104 and 156

  2. Change From Baseline in Modified Rankin Scale (mRS) Score

    Disease-related disability was measured by the mRS score. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered from a neurological disability. The scale ranges from 0 (no symptoms at all) to 6 (death) in whole-point increments. A decrease in score indicates improvement. Baseline was defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.

    Time frame: Baseline, Weeks 52, 104 and 156

  3. Change From Baseline in Hauser Ambulation Index (HAI) in Participants With Abnormal Baseline Ambulatory Function

    The HAI evaluates gait and was used to assess the time and effort used by the participant to walk 25 feet (8 meters). The scale ranges from 0 to 9, with 0 being the best score (asymptomatic; fully active) and 9 being the worst (restricted to wheelchair; unable to transfer self independently). A decrease in score indicates improvement. Baseline is defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.

    Time frame: Baseline, Weeks 52, 104 and 156

  4. Change From Baseline in European Quality of Life (EuroQoL) 5-Dimension Visual Analog Scale (EQ-5D VAS) Health Status Score

    The EQ-5D is a generic, standardized participant self-administered health status instrument. EQ-5D general health status can also be measured by a visual analog scale (EQ-5D VAS). EQ-5D-VAS recorded the participant's self-rated health on a vertical visual analog scale (VAS) that allowed the participants to indicate their health state that ranged from 0 (worst imaginable) to 100 (best imaginable). Baseline is defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.

    Time frame: Baseline, Weeks 52, 104 and 156

  5. Change From Baseline in Kurtzke Visual Functional System Scores (FSS) in Participants With Abnormal Baseline Visual Function

    The EDSS assesses multiple Kurtzke functional systems in the context of a standard neurological exam, including visual function. The visual score ranges from 0 to 6. A score of 0 implies the participant has normal visual function. Higher scores represent worse disability. Baseline is defined as the last available assessment prior to the first study drug infusion in Study EC-NMO-302.

    Time frame: Baseline, Weeks 52, 104 and 156

07

Results

Posted Aug 23, 2022

Participant flow

Blind Induction Phase
Participant flow — Blind Induction Phase
MilestonePlacebo/EculizumabEculizumab/Eculizumab
Started4178
Received at least 1 dose of study drug4178
Completed4178
Not completed00
Open Label Maintenance Phase
Participant flow — Open Label Maintenance Phase
MilestonePlacebo/EculizumabEculizumab/Eculizumab
Started4178
Received at least 1 dose of study drug4178
Completed3264
Not completed914
Withdrew: Other than specified24
Withdrew: Withdrawal by subject45
Withdrew: Pregnancy02
Withdrew: Physician decision11
Withdrew: Lost to follow-up01
Withdrew: Adverse event21

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events and Serious Adverse Events

An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent adverse events (TEAEs) were defined as an AE with onset on or after the first study drug dose in Study ECU-NMO-302. A serious adverse event (SAE) was defined as an untoward medical occurrence that at any dose either results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline up to end of study (up to 6.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events
ParticipantsPlacebo/EculizumabEculizumab/Eculizumab
TEAEs4170
SAEs1426
PrimaryNumber of Participants With At Least 1 Post Baseline Columbia-Suicide Severity Rating Scale (C-SSRS) Assessment (Suicide-Related Thoughts or Behaviours) Abnormality

The C-SSRS is a validated questionnaire to capture occurrence, severity, and frequency of suicide-related thoughts and behaviours, and has a binary response (yes/no). Suicidal Ideation: a "yes" answer to any one of 5 suicidal ideation questions: Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Planned) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; and Active Suicidal Ideation with Specific Plan and Intent. Suicidal Behaviour: a "yes" answer to any of 5 suicidal behaviour questions: Preparatory Acts or Behaviour, Aborted Attempt, Interrupted Attempt, Actual Attempt (non-fatal), and Completed Suicide. Suicidal Ideation or Behaviour: a "yes" answer to the following question: Self-injurious behaviour without suicidal intent.

Time frame:
Baseline up to end of study (up to 6.5 years)
Reported as:
Count of participants · Participants
Number of Participants With At Least 1 Post Baseline Columbia-Suicide Severity Rating Scale (C-SSRS) Assessment (Suicide-Related Thoughts or Behaviours) Abnormality
ParticipantsPlacebo/EculizumabEculizumab/Eculizumab
Suicidal Ideation45
Suicidal Behavior01
Suicidal Ideation or Behavior45
PrimaryNumber of Participants With An On-trial Relapse as Determined by The Treating Physician

An On-trial Relapse was defined as a new onset of neurologic symptoms or worsening of existing neurologic symptoms with an objective change (clinical sign) on neurologic examination that persisted for more than 24 hours as confirmed by the treating physician.

Time frame:
Baseline up to end of study (up to 6.5 years)
Reported as:
Count of participants · Participants
Number of Participants With An On-trial Relapse as Determined by The Treating Physician
ParticipantsPlacebo/EculizumabEculizumab/Eculizumab
Number of Participants With An On-trial Relapse as Determined by The Treating Physician58
PrimaryOn-Trial Annualized Relapse Rate (ARR) as Determined by The Treating Physician

The On-trial ARR was computed as the total number of relapses divided by the total number of participant years in the study period.

Time frame:
Baseline up to end of study (up to 6.5 years)
Reported as:
Mean · relapses/years on study
On-Trial Annualized Relapse Rate (ARR) as Determined by The Treating Physician
relapses/years on studyPlacebo/EculizumabEculizumab/Eculizumab
On-Trial Annualized Relapse Rate (ARR) as Determined by The Treating Physician0.128 ± 0.45760.061 ± 0.2186
SecondaryChange From Baseline in Expanded Disability Status Scale (EDSS) Score

Disease-related disability was measured by the EDSS. The EDSS quantifies disability in 8 Functional Systems (FS) and allows neurologists to assign a Functional System Score (FSS) in each of these. The Functional Systems are pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral, and other. The EDSS is an ordinal clinical rating scale that ranges from 0 (normal neurologic examination) to 10 (death) in half-point increments. A decrease in score indicates improvement. Baseline was defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.

Time frame:
Baseline, Weeks 52, 104 and 156
Reported as:
Mean · units on a scale
Change From Baseline in Expanded Disability Status Scale (EDSS) Score
units on a scalePlacebo/EculizumabEculizumab/Eculizumab
Baseline4.34 ± 1.8793.97 ± 1.736
Change from Baseline at Week 52-0.24 ± 0.7210.01 ± 0.571
Change from Baseline at Week 104-0.39 ± 0.830-0.11 ± 0.536
Change from Baseline at Week 156-0.38 ± 1.003-0.38 ± 1.057
SecondaryChange From Baseline in Modified Rankin Scale (mRS) Score

Disease-related disability was measured by the mRS score. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered from a neurological disability. The scale ranges from 0 (no symptoms at all) to 6 (death) in whole-point increments. A decrease in score indicates improvement. Baseline was defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.

Time frame:
Baseline, Weeks 52, 104 and 156
Reported as:
Mean · units on a scale
Change From Baseline in Modified Rankin Scale (mRS) Score
units on a scalePlacebo/EculizumabEculizumab/Eculizumab
Baseline2.39 ± 1.3581.88 ± 1.269
Change from Baseline at Week 52-0.27 ± 0.932-0.04 ± 0.458
Change from Baseline at Week 104-0.41 ± 1.182-0.14 ± 0.543
Change from Baseline at Week 156-0.62 ± 1.446-0.31 ± 0.602
SecondaryChange From Baseline in Hauser Ambulation Index (HAI) in Participants With Abnormal Baseline Ambulatory Function

The HAI evaluates gait and was used to assess the time and effort used by the participant to walk 25 feet (8 meters). The scale ranges from 0 to 9, with 0 being the best score (asymptomatic; fully active) and 9 being the worst (restricted to wheelchair; unable to transfer self independently). A decrease in score indicates improvement. Baseline is defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.

Time frame:
Baseline, Weeks 52, 104 and 156
Reported as:
Mean · units on a scale
Change From Baseline in Hauser Ambulation Index (HAI) in Participants With Abnormal Baseline Ambulatory Function
units on a scalePlacebo/EculizumabEculizumab/Eculizumab
Baseline2.83 ± 2.1232.35 ± 2.257
Change from Baseline at Week 52-0.44 ± 1.1320.08 ± 0.816
Change from Baseline at Week 104-0.57 ± 1.7770.07 ± 1.033
Change from Baseline at Week 156-1.08 ± 1.7060.07 ± 1.269
SecondaryChange From Baseline in European Quality of Life (EuroQoL) 5-Dimension Visual Analog Scale (EQ-5D VAS) Health Status Score

The EQ-5D is a generic, standardized participant self-administered health status instrument. EQ-5D general health status can also be measured by a visual analog scale (EQ-5D VAS). EQ-5D-VAS recorded the participant's self-rated health on a vertical visual analog scale (VAS) that allowed the participants to indicate their health state that ranged from 0 (worst imaginable) to 100 (best imaginable). Baseline is defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.

Time frame:
Baseline, Weeks 52, 104 and 156
Reported as:
Mean · units on a scale
Change From Baseline in European Quality of Life (EuroQoL) 5-Dimension Visual Analog Scale (EQ-5D VAS) Health Status Score
units on a scalePlacebo/EculizumabEculizumab/Eculizumab
Baseline62.00 ± 22.01272.27 ± 20.941
Change from Baseline at Week 522.22 ± 13.294-0.78 ± 12.388
Change from Baseline at Week 1040.05 ± 18.8671.28 ± 11.295
Change from Baseline at Week 15611.00 ± 19.374-4.13 ± 18.421
SecondaryChange From Baseline in Kurtzke Visual Functional System Scores (FSS) in Participants With Abnormal Baseline Visual Function

The EDSS assesses multiple Kurtzke functional systems in the context of a standard neurological exam, including visual function. The visual score ranges from 0 to 6. A score of 0 implies the participant has normal visual function. Higher scores represent worse disability. Baseline is defined as the last available assessment prior to the first study drug infusion in Study EC-NMO-302.

Time frame:
Baseline, Weeks 52, 104 and 156
Reported as:
Mean · units on a scale
Change From Baseline in Kurtzke Visual Functional System Scores (FSS) in Participants With Abnormal Baseline Visual Function
units on a scalePlacebo/EculizumabEculizumab/Eculizumab
Baseline3.75 ± 2.0303.60 ± 2.031
Change from Baseline at Week 52-0.08 ± 0.392-0.06 ± 0.569
Change from Baseline at Week 104-0.13 ± 0.352-0.10 ± 0.651
Change from Baseline at Week 1560.00 ± 0.000-0.29 ± 0.994

Adverse events

Collected over Baseline up to end of study (up to 6.5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/Eculizumab0/41 (0%)14/41 (34.1%)40/41 (97.6%)
Eculizumab/Eculizumab0/78 (0%)26/78 (33.3%)70/78 (89.7%)
Eculizumab (Combined Total)0/119 (0%)40/119 (33.6%)110/119 (92.4%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventPlacebo/EculizumabEculizumab/EculizumabEculizumab (Combined Total)
Cholecystitis acuteHepatobiliary disorders2/411/783/119
Urinary tract infectionInfections and infestations2/413/785/119
Neuromyelitis optica spectrum disorderNervous system disorders2/413/785/119
Pyelonephritis acuteInfections and infestations0/412/782/119
UrosepsisInfections and infestations0/412/782/119
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/412/782/119
Optic neuritisNervous system disorders1/412/783/119
LymphadenopathyBlood and lymphatic system disorders1/410/781/119
Irritable bowel syndromeGastrointestinal disorders1/410/781/119
AstheniaGeneral disorders1/410/781/119
Most frequent other events
Showing 10 of 47
Most frequent other events
EventPlacebo/EculizumabEculizumab/EculizumabEculizumab (Combined Total)
NasopharyngitisInfections and infestations16/4113/7829/119
HeadacheNervous system disorders12/4115/7827/119
Upper respiratory tract infectionInfections and infestations11/4117/7828/119
Urinary tract infectionInfections and infestations11/4113/7824/119
InfluenzaInfections and infestations9/4110/7819/119
DiarrhoeaGastrointestinal disorders8/416/7814/119
ArthralgiaMusculoskeletal and connective tissue disorders8/4115/7823/119
NauseaGastrointestinal disorders7/413/7810/119
CoughRespiratory, thoracic and mediastinal disorders7/415/7812/119
PyrexiaGeneral disorders6/4112/7818/119

Baseline characteristics

The Extension Full Analysis Set consisted of all participants who had received at least 1 dose of eculizumab in Study ECU-NMO-302 and have a post-IP-infusion efficacy assessment.

Age, Continuous
Age, Continuous(years)Placebo/EculizumabEculizumab/EculizumabTotal
Mean46.0 ± 13.8246.6 ± 13.7746.4 ± 13.73
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/EculizumabEculizumab/EculizumabTotal
Female3674110
Male549
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo/EculizumabEculizumab/EculizumabTotal
Hispanic or Latino21113
Not Hispanic or Latino3763100
Unknown or Not Reported246
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo/EculizumabEculizumab/EculizumabTotal
American Indian or Alaska Native011
Asian133245
Black or African American7310
White214061
Other011
Unknown or Not Reported011
08

Study locations

69 sites
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
  • The Research Center of Southern California
    Oceanside, California 92056, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • University of Miami McKnight Brain Institute
    Miami, Florida 33136, United States
  • Neurological Services of Orlando
    Orlando, Florida 32806, United States
  • Allied Physicians Inc. of Fort Wayne
    Fort Wayne, Indiana 46805, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Baptist Health Lexington
    Nicholasville, Kentucky 40503, United States
  • Johns Hopkins University Medical Center
    Baltimore, Maryland 21287, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Multiple Sclerosis Comprehensive Care Center NYU Langone Medical Center
    New York, New York 10016, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Ohio Health Reserach Institute
    Columbus, Ohio 43214, United States
  • University of Pennsylvania School of Medicine
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15232, United States
  • Multiple Sclerosis Treatment Center of Dallas
    Dallas, Texas 75246, United States
  • The University of Texas Health Science
    San Antonio, Texas 78229, United States
  • University of Utah
    Salt Lake City, Utah 84108, United States
  • Hospital Universitario Austral
    Pilar, Buenos Aires B1629ODT, Argentina
  • Fundacion Rosarina de Neuro Rehabilitacion
    Rosario, Santa Fe S2000BZL, Argentina
  • Hospital General de Agudos Dr. J. M. Ramos Mejia
    Ciudad Autonoma, Buenos Aires,, C1221ADC, Argentina
  • Hospital General de Agudos Juan Antonio Fernandez
    Ciudad Autonoma, Buenos Aires, C1425AGP, Argentina
  • Brain and Mind Research Institute
    Camperdown, New South Wales, Australia
  • St. Vincent's Hospital
    Fitzroy, Victoria 3065, Australia
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Fundacion Cardiovascular de Colombia
    Floridablanca, Santander, Colombia
  • Clinical Hospital Centre Zagreb
    Zagreb, 10000, Croatia
  • VFN v Praze
    Praha, Czechia
  • Krajska zdravotni, a.s. - Nemocnice
    Teplice, 415 01, Czechia
  • Århus Universitetshospital
    Arhus, 8000, Denmark
  • University Hospital Heidelberg
    Heidelberg, Baden Wuerttemberg 69120, Germany
  • Neurologische Klinik und Poliklinik
    Munich, Bayern 81675, Germany
  • University Hospital Heinrich Heine University
    Dusseldorf, Nordrhein Westfalen 40225, Germany
  • Universitaetsmedizin Rostock
    Rostock, 18147, Germany
  • Prince of Wales Hospital
    Shatin, Hong Kong
  • Policlinico di Catania
    Catania, 95123, Italy
  • Azienda Ospedaliera Universitaria
    Napoli, 80131, Italy
  • Azienda Ospedaliera di Padova
    Padova, 35128, Italy
  • Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza
    Rome, 00178, Italy
  • Chiba University Hospital
    Chiba-shi, Chiba-Ken 260-8677, Japan
  • Hyogo College of Medicine Hospital
    Nishinomiya-shi, HyogoKen, Japan
  • Kyoto Min-iren Chuo Hospital
    Kyoto-shi, Kyoto-Fu 604-8453, Japan
  • Tohoku University Hospital
    Sendai-shi, Miyagi-Ken 980-8574, Japan
  • Yamaguchi University Hospital
    Ube-shi, Yamaguchi-Ken 755-8505, Japan
  • Kyushu University Hospital
    Fukuoka, 812-8582, Japan
  • National Center Hospital, NCNP
    Tokio, Japan
  • National Cancer Center
    Goyang-si, Gyeonggi-do 410-769, Korea, Republic of
  • Seoul University National Hospital
    Seoul, 110744, Korea, Republic of
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 136-705, Korea, Republic of
  • Severance Hospital, Yonsei University
    Seoul, 136-705, Korea, Republic of
  • Hospital Umum Sarawak
    Kuching, Sarawak 93586, Malaysia
  • Hospital Kuala Lumpur
    Kuala Lumpur, 50586, Malaysia
  • Republican Clinical Hospital for Rehabilitation of Healthcare Ministry of Republic of Tatarstan
    Kazan, 420021, Russian Federation
  • SBEI "Krasnoyarsk SMU n.a. Prof. V.F. Voyno-Yasenetsky"
    Krasnoyarsk, 660037, Russian Federation
  • Federal State Budget Institution of Healthcare - Siberian District Medical Center of FMBA of Russia
    Novosibirsk, 630068, Russian Federation
  • SEIHPE "Rostov SMU of MoH of RF"
    Rostov-on Don, Russian Federation
  • Hospital de Cruces
    Barakaldo, Bizkaia 48903, Spain
  • Hospital Universitario Reina Sofia
    Cordoba, 14404, Spain
  • Hospital Universitario Clinico San Carlos
    Madrid, 28040, Spain
  • Cheng Hsin General Hospital
    Taipei, Taiwan
  • Thammasat University Hospital
    Pathum Thani, Thailand
  • Hacettepe University Medical Faculty
    Ankara, 06100, Turkey
  • Trakya University Medical Faculty
    Edirne, Turkey
  • Dokuz Eylul University Medicine Faculty
    Izmir, 35340, Turkey
  • Kocaeli University Medical Faculty
    Kocaeli, Turkey
  • Ondokuz Mayis Univ. Med. Fac.
    Samsun, Turkey
  • The Walton Centre
    Liverpool, L97LJ, United Kingdom
09

References and documents

Publications

  • Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013 Jun;12(6):554-62. doi: 10.1016/S1474-4422(13)70076-0. Epub 2013 Apr 26. PubMed 23623397 ↗
  • Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, Nakashima I, Levy M, Shang S, Yountz M, Miller L, Armstrong R, Wingerchuk DM; PREVENT Study Group. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Mult Scler. 2022 Mar;28(3):480-486. doi: 10.1177/13524585211038291. Epub 2021 Sep 9. PubMed 34498507 ↗
  • Kim HJ, Nakashima I, Viswanathan S, Wang KC, Shang S, Miller L, Yountz M, Wingerchuk DM, Pittock SJ, Levy M, Berthele A, Totolyan N, Palace J, Barnett MH, Fujihara K; PREVENT Study Group. Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. Mult Scler Relat Disord. 2021 May;50:102849. doi: 10.1016/j.msard.2021.102849. Epub 2021 Feb 20. PubMed 33676197 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2015 to primary completion in Jul 2021, 78 months.

Results were first posted in Aug 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2013
First posted
Dec 6, 2013
StartActual
Jan 12, 2015
Primary completionActual
Jul 12, 2021
CompletionActual
Jul 12, 2021
Results first posted
Aug 23, 2022
Last update
Aug 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02003144
Responsible party
Sponsor
First posted
Dec 6, 2013
Start date
Jan 12, 2015
Primary completion
Jul 12, 2021
Completion
Jul 12, 2021
Results posted
Aug 23, 2022
Last update
Aug 23, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion